Inactivation of p53, the master regulator of cellular stress and damage signals, often allows cells that should die or senesce to live. Loss of Dicer, an RNase III-like enzyme critical in microRNA biogenesis, causes embryonic lethality and activation of the p53 pathway. Several nonhematopoietic cell types that contain inactivated p53 have been shown to survive Dicer deletion, suggesting that p53 loss may protect cells from the negative consequences of Dicer deletion. However, here, we report that loss of p53 did not provide a survival advantage to B cells, as they underwent rapid apoptosis upon Dicer deletion. Moreover, a deficiency in p53 neither rescued the Dicer deletioninduced delay in Myc-driven B-cell lymphomagenesis, nor allowed a single B-cell lymphoma to develop with biallelic deletion of Dicer. A p53 deficiency did, however, restore the pre-B/B-cell phenotype and CD19 surface expression of the lymphomas that emerged in conditional Dicer knockout Em-myc transgenic mice. Moreover, p53 loss in transformed B cells did not confer protection from apoptosis, as Dicer deletion in established p53-null Bcell lymphomas induced apoptosis, and all of the 1,260 B-cell lymphoma clones analyzed that survived Cremediated Dicer deletion retained at least one allele of Dicer. Moreover, Dicer deletion in lymphomas in vivo reduced tumor burden and prolonged survival. Therefore, inactivation of p53 is insufficient to allow untransformed B cells and B-cell lymphomas to survive without Dicer, presenting a potential therapeutic opportunity for the treatment of B-cell lymphomas. Cancer Res; 74(14); 3923-34. Ó2014 AACR.
Introduction microRNA (miRNA) are small noncoding RNA that regulate gene expression posttranscriptionally and have essential roles in development, proliferation, apoptosis, and transformation (1, 2) . Alterations in miRNA expression are linked to tumor development, including hematopoietic malignancies (1) (2) (3) . Moreover, the oncogene c-Myc, which is frequently overexpressed in many human malignancies and a driver of B-cell lymphomagenesis, transcriptionally regulates the expression of many miRNA (4) .
miRNA are transcribed in a precursor form and processed with enzymes, such as Dicer, an RNase III-like enzyme with critical roles in cell differentiation, proliferation, and survival (5) . Loss of one allele of DICER or reduced DICER expression or enzymatic activity is reported in multiple solid organ tumors (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Mouse models revealed Dicer is a haploinsufficient tumor suppressor in soft tissue sarcoma, lung adenocarcinoma, and retinoblastoma (17, 18) . In contrast, we showed that Dicer heterozygosity had no effect on the rate of B-cell lymphoma development (19) . Therefore, differences in the requirements for Dicer and the effects of reduced Dicer expression in different tissues remain unresolved.
The p53 tumor suppressor, which induces apoptosis or cellcycle arrest upon cellular stresses (20) , responds to defects in miRNA biogenesis, and therefore, may be required to signal problems in this pathway. Specifically, in untransformed murine embryonic fibroblasts (MEF), deletion of Dicer leads to p53 activation and premature senescence, which is delayed with loss of p53 (21) . We previously detected an increased frequency of p53 inactivation in lymphomas in a mouse model of Myc-induced B-cell lymphoma (Em-myc) expressing B-celldirected Cre and two conditional Dicer alleles, suggesting a connection between p53 activation and Dicer deletion in B cells (19) . Moreover, data from three groups, including our own, showed expression of Cre in Dicer fl/fl mice in B-cell progenitors or mature B cells results in B-cell apoptosis (19, 22, 23) . This apoptosis was partially rescued by overexpressing the antiapoptotic Bcl-2 protein or reducing the proapoptotic Bim protein (22) . Although p53-null murine sarcoma cells and p53-inactivated mesenchymal stem cells can survive Dicer deletion (23), p53 deletion was synthetically lethal in Dicer and Rb-deficient retinal progenitor cells (24) . Therefore, the role of p53 in monitoring defects in miRNA biogenesis and cell survival in the context of a Dicer deficiency remains unclear.
Using mouse models, we determined the contribution of p53 to B-cell survival and lymphoma development with loss of Dicer. A p53 deficiency did not rescue the defect in B-cell development, the reduction in B-cell survival, or the delay in Myc-induced lymphomagenesis upon Dicer deletion. It did restore the B-cell lymphoma phenotype. However, none of the lymphomas that emerged had deleted both alleles of Dicer. Moreover, established B-cell lymphomas lacking p53 underwent apoptosis when Dicer was deleted, significantly extending survival in mouse models. Thus, p53 loss is insufficient to allow survival and growth of B cells and B-cell lymphomas in the absence of Dicer, and thus, targeting Dicer may have therapeutic potential for treating B-cell lymphomas.
Materials and Methods

Mice
C57Bl/6 Em-myc (25) and CD19-cre (26) ) were injected (subcutaneous or intravenous, respectively) into 6-week-old Foxn1 nu/nu female mice (Harlan Laboratories). Tamoxifen (2 mg) or corn oil (vehicle control) was injected (intraperitoneal) once daily for 3 days starting the day of lymphoma injection for two cohorts (one subcutaneous and one tail vein injected cohort) or after lymphomas were 90 to 150 mm 3 for a second subcutaneous cohort. Subcutaneous tumors were measured with calipers and tumor volume was calculated. Blood was collected for flow cytometric and microscopic analyses from the mice where lymphoma was injected into the tail vein. Mice were humanely sacrificed before lymphoma development or for survival studies, at humane endpoints, and tumors/tissues were harvested and analyzed. Log-rank tests determined statistical significance for survival. All studies were in accordance with state and federal guidelines and were approved by the Vanderbilt Institutional Animal Care and Use Committee.
Western and Southern blotting
Whole-cell protein lysates from B-cell lymphomas and pre-B cells were generated and Western blotted as previously described (28) . Antibodies against p19Arf (GeneTex), p53 (Ab-7; Calbiochem), Mdm2 (C-18; Santa Cruz Biotechnology), Cre (Novagen), Dicer (Cell Signaling Technology), cleaved caspase-3 (Cell Signaling Technology), and b-actin (Sigma) were used. As previously described (28, 29) , p53 was sequenced and Southern blot analyses for p53 with genomic DNA from lymphomas were performed.
Phenotype analysis
Lymphoma cells and splenocytes from littermates before lymphoma development were analyzed by flow cytometry following incubation with fluorochrome-linked antibodies against surface receptors as previously reported (19, 29) .
Quantitative real-time PCR
Total RNA was isolated from lymphomas with TRIzol (Invitrogen) according to the manufacturer's protocol. As previously described, cDNA was generated, and SYBR Green (SABiosciences) and TaqMan MicroRNA Assays (Applied Biosciences) were used to perform qRT-PCR, in triplicate, for mRNA and miRNA analysis, respectively (19, 30) . mRNA and miRNA expression were normalized to b-actin and RNU6b expression, respectively, and the data were presented as 2 ÀDC t .
Dicer gene rearrangement analysis Genomic DNA was isolated from frozen and cultured lymphomas, pre-B cells, and MEFs using the REDExtract-N-Amp Tissue PCR Kit (Sigma). PCR was performed with primers specific for unrearranged and Cre-lox-deleted Dicer alleles, as previously published (19, 21) . PCR conditions allowed for 10% to 15% contaminating normal tissue without detecting unrearranged floxed Dicer alleles.
Pre-B cell and lymphoma cell survival analyses
Primary pre-B cell cultures from p53
, and p53 À/À /Dicer þ/fl mice and primary p53-deleted or Arf-deleted Dicer þ/fl or Dicer fl/fl Em-myc lymphoma cells were generated as previously described (19, 28) . Cells were infected with a bicistronic retrovirus (MSCV) encoding CreER T2 (31) and GFP or GFP alone. Cell number and viability were determined by Trypan Blue Dye exclusion assays and proliferation was measured by MTS assays (490 nm; CellTiter 96 AQueous One Solution Cell Proliferation Assay; Promega), after plating equal numbers of cells, in triplicate, and adding 1 mmol/L 4-hydroxytamoxifen (4-OHT) or vehicle (ethanol) control. Apoptosis was evaluated by Western blotting for cleaved caspase-3 and by flow cytometry following propidium iodide staining for fragmented (sub-G 1 ) DNA and Annexin V/7-AAD staining after adding 1 mmol/L 4-OHT or vehicle (ethanol) control in triplicate, in vitro, or after administering tamoxifen or vehicle (corn oil) for the nude mouse experiments. For single-cell analyses, GFPpositive lymphoma cells were placed one cell/well into 96-well plates by a flow cytometer and visually inspected. Vehicle (ethanol) control or 4-OHT (1 mmol/L) was added to each well and surviving clones were harvested and Dicer gene rearrangement was determined by PCR.
Results
p53 deficiency does not rescue lymphoma latency in Mycoverexpressing Dicer fl/fl mice Previously, we reported that Dicer deletion in B-cell precursors resulted in delayed Myc-induced B-cell lymphoma development and the inability of a B-cell lymphoma to emerge with biallelic Dicer deletion (19) . To determine whether B-cell lymphomas could develop without Dicer in the context of a p53 deficiency, we generated p53 /Em-myc mice and littermate controls that were also transgenic for B lineagerestricted CD19-cre recombinase; p53-null Em-myc mice cannot be generated (26) . c-Myc in Em-myc transgenic mice and Cre in CD19-cre transgenic mice are first expressed in B-cell precursors and continue throughout the life of the B-cell (25, 26) . There was a pronounced delay in lymphomagenesis and extended survival in CD19-cre log-rank test). All but one (DC1122) of the 23 lymphomas analyzed lacked p53 protein expression, and all overexpressed p19Arf protein, an indicator of p53 inactivation (subset of those analyzed is shown in Fig. 1B) . Sequencing of p53 in DC1122 revealed a mutation (G263R) in its DNA binding domain. Southern blot analyses showed that all lymphomas lacking p53 protein had deleted their wild-type allele of p53 (representative data of those analyzed are shown in Fig. 1C) . Therefore, all lymphomas were functionally p53-null. In addition, Mdm2, a negative regulator of p53, was overexpressed in 35% of the lymphomas (Fig. 1B) . Thus, there was a delay in Myc-induced lymphomagenesis caused by Dicer deletion in p53 heterozygous mice, and a deficiency in Dicer did not alter selection for p53 inactivation in the lymphomas that arose.
Dicer is not a haploinsufficient tumor suppressor in Mycinduced B-cell lymphoma (19) . To determine whether a p53 deficiency would allow Dicer to function as a haploinsufficient tumor suppressor in B cells, we evaluated B-cell lymphoma development in the context of Dicer heterozygosity. Cre-positive and Cre-negative p53
þ/fl /Emmyc transgenic mice had a similar rate of lymphoma development with mean survivals of 35 and 36 days, respectively (Fig. 1A) . The evaluation of lymphomas that developed in CD19-cre
(17 of 17 analyzed) lacked p53 protein, due to deletion of the wild-type allele, and overexpressed Arf (subset of those analyzed is shown in Fig. 1D and E). These results indicate that a p53 deficiency did not allow Dicer heterozygosity to accelerate B-cell lymphomagenesis.
Loss of p53 rescues the type of B-cell lymphoma that develops Previously, we determined that approximately 40% of the lymphomas that emerged in CD19-cre þ /Dicer fl/fl /Em-myc mice were of very early precursor B-cell origin, B220
. We evaluated whether a p53 deficiency would alter the development or frequency of this phenotype by assessing lymphomas from p53
Fourteen of the 16 (88%) lymphomas analyzed were typical Em-myc pre-B and/or B-cell lymphomas (25) and expressed B220 and CD19, and were either IgM Table 1) . Unexpectedly, 2 of 16 lymphomas were CD3 þ/À /CD19-cre þ /Em-myc mice were typical Em-myc lymphomas (Table 1) . Thus, a p53 deficiency fully restored development of the characteristic Em-myc B-cell lymphoma in CD19-cre þ /Dicer fl/fl /Em-myc mice, but it also allowed T-cell lymphomas to develop.
A deficiency in p53 rescues CD19 expression in B-cell lymphomagenesis CD19 expression was absent or decreased in 65% of the lymphomas from CD19-cre þ /Dicer fl/fl /Em-myc mice, resulting in reduced or absent Cre expression (19) . Preventing CD19 expression was one mechanism by which lymphomas could avoid Dicer deletion. To assess the consequences of a p53 deficiency on CD19 expression in the lymphomas in this study, we evaluated p53 showed that they all expressed Cre protein (Fig. 2D ). Therefore, a deficiency in p53 rescued CD19 surface expression and partially restored Cre expression in B-cell lymphomas from CD19-cre þ /Dicer fl/fl /Em-myc mice.
p53 deficiency is insufficient to allow Dicer deletion during B-cell lymphomagenesis We previously reported that not a single lymphoma from CD19-cre þ /Dicer fl/fl /Em-myc mice had deleted both Dicer alleles (19) . In this study, we assessed whether the exons flanked by loxP sites in the Dicer gene had been deleted. The evaluation of Dicer heterozygous p53 þ/À /CD19-cre þ /Em-myc lymphomas showed that all 17 analyzed had deleted their one floxed Dicer allele (Fig. 3A) . However, 11 of 23 (48%) lymphomas analyzed from Dicer fl/fl /p53 þ/À /CD19-cre þ /Em-myc mice deleted one conditional Dicer allele, whereas the other 12 lymphomas retained both floxed alleles (Fig. 3B) . None of the Table 1 . Dicer fl/fl Em-myc lymphoma phenotypes are rescued with a p53 deficiency Lymphomas with one allele of Dicer expressed an analogous amount of Dicer protein as lymphomas that retained both alleles of Dicer (Fig. 3C) . Moreover, mature miRNA transcript levels of miR20a and miR31, Dicer-dependent miRNA, were similar regardless of Dicer status in all lymphomas analyzed (Fig. 3D) . These data indicate that all lymphomas, including those with only one Dicer allele, expressed wild-type levels of Dicer that was fully functional in miRNA biogenesis.
p53 loss cannot rescue B-cell development following Dicer deletion
In vivo, biallelic Dicer deletion in developing B cells with wild-type p53 induces apoptosis, causing a developmental defect, resulting in decreased mature splenic B cells (19, 22) . Protecting B cells from this apoptosis partially rescues B-cell development (22) . Because a p53 deficiency rescued the pre-B/B-cell lymphoma phenotype in CD19-cre þ /Dicer fl/fl /Emmyc mice, we questioned whether p53 mediates the Dicer deletion-induced B-cell apoptosis. To address this, we evaluated splenic B cells from precancerous p53 À/À and p53 (Fig. 4B-E) , as would be expected for pre-B cells with one wild-type Dicer allele. Dicer gene rearrangement was assessed in the surviving pre-B cells and showed that, regardless of genotype, only one Dicer allele was rearranged in the CreER T2 -activated pre-B cells (Fig. 4F) . Notably, Dicer fl/fl fibroblasts containing similar levels of CreER T2 protein (Fig. 4B ) deleted both floxed Dicer alleles (Fig.  4F) . Therefore, loss of p53 could not rescue the rapid apoptosis induced by biallelic Dicer deletion in primary untransformed pre-B cells, and only pre-B cells that had retained one allele of Dicer could survive. Dicer is required for B-cell lymphoma survival Recently, Sharp and colleagues reported that a p53-null murine sarcoma cell line could survive and proliferate without Dicer (23), suggesting cellular transformation may alter the requirements for Dicer. We tested whether transformed B cells could survive loss of Dicer if they also lacked p53. B-cell lymphomas were isolated from two p53 þ/À /Dicer fl/fl /Em-myc mice (DC1020 and DC1185) and as controls from two p53
/Em-myc mice (DC2385 and DC2423). p53 protein was not detected by Western blot analysis, and Southern blot analysis showed deletion of the remaining wild-type allele of p53 in all four lymphomas (Figs. 1D and E and 5A). The lymphomas were infected with a bicistronic retrovirus encoding CreER T2 and GFP or GFP alone. CreER T2 activation with 4-OHT in the p53-deleted Dicer þ/fl /Em-myc lymphomas had no effect on cell number compared with a p53-deleted Dicer fl/fl /Em-myc lymphoma, which showed a significant decrease in cell number after CreER T2 activation ( Fig. 5B and Supplementary Fig. S1 ). CreER T2 activation in both p53-deleted Dicer fl/fl /Em-myc lymphomas resulted in apoptosis, whereas there was little effect following addition of vehicle control or 4-OHT to lymphomas infected with empty retrovirus ( Fig. 5C-F) . Specifically, the total number and viability of CreER T2 p53-deleted Dicer fl/fl /Em-myc lymphoma cells decreased, whereas the percentage of apoptotic cells (cells with fragmented, sub-G 1 DNA, or that were Annexin V þ )
increased after addition of 4-OHT (Fig. 5C-F) . PCR analysis revealed that the p53-deleted Dicer þ/fl /Em-myc lymphoma cells deleted their one floxed Dicer allele, whereas the p53-deleted Dicer fl/fl /Em-myc lymphoma cells surviving CreER T2 activation had only deleted one of the conditional Dicer alleles (Fig. 5G) . Analogous results were obtained with Dicer fl/fl /Em-myc B-cell lymphomas that had deleted Arf and retained p53 (Supplementary Fig. S2 ). We postulated that it was possible for preferential outgrowth of lymphoma cells possessing one allele of Dicer, masking the presence of a small population of lymphoma cells that had deleted both alleles of Dicer. To evaluate this possibility, we performed single-cell sorting for GFP-positive cells of two independent CreER T2 -expressing p53-deleted Dicer fl/fl /Em-myc lymphoma lines into 96-well plates. After visually confirming the presence of a single cell per well, CreER T2 was activated with 4-OHT, and the surviving clones were assessed. Only 26% (328 of 1,260) of the clones survived /Em-myc lymphoma cell line (DC561) from our previous study (19) were subjected to Western blot analysis (left) for the proteins indicated and Southern blot analysis (right and Fig. 1E ) for p53. A lymphoma containing mutant p53 was a control for the Western blot analysis. Lymphomas that contain (þ) or have deleted (Del) p53 were controls for the Southern blot analysis.
Ã ,the DNA loading control, the p53 pseudogene. B-F, DC1020, DC1185, DC2385, and/or DC2423 lymphoma cells were infected with a CreER 
CreER
T2 activation, whereas 98.5% (394 of 400) of the vehicle-treated clones grew out. Analysis of all 328 lymphoma clones that survived CreER T2 activation revealed that none had deleted both Dicer alleles (a subset of those analyzed is shown in Fig. 5H ). Instead, 306 (93.3%) had deleted one Dicer allele, whereas the other 22 (6.7%) maintained both floxed alleles. Moreover, analysis of the Dicer fl/fl /Em-myc lymphoma used in the single-cell analysis in our previous study (DC561; ref. 19 ) in which we obtained analogous results, revealed that it had biallelic p53 deletion (Fig. 5A) . Collectively, these data illustrate that B-cell lymphomas cannot survive without Dicer, even when p53 is deleted. Therefore, at least one allele of Dicer is required for B-cell lymphoma survival.
In vivo Dicer deletion inhibits lymphoma growth and extends survival Given that B-cell lymphomas require Dicer for survival, in vitro, we tested whether inactivating Dicer would alter lymphoma growth in vivo with three different mouse experiments. First, p53-deleted Dicer fl/fl /Em-myc lymphoma cells (DC1020) expressing CreER T2 were subcutaneously injected into nude mice and CreER T2 was activated by tamoxifen the same day. There was a significant delay in lymphoma progression and extended survival in the mice that received tamoxifen compared with the vehicle-treated mice ( Fig. 6A ; P ¼ 0.0012, log-rank test). Tumors from vehicle-treated mice grew significantly larger more quickly compared with tumors from mice that received tamoxifen to activate CreER T2 ( Fig. 6B ; Ã , P ¼ 0.0051; ÃÃ , P < 0.003). To determine whether loss of Dicer would affect established lymphomas, we allowed a cohort of mice to grow subcutaneous lymphomas of 90 to 150 mm 3 and then administered tamoxifen or vehicle control (tumor sizes were matched between groups; Fig. 6C and D) . Although the rapid rate of tumor growth continued in the vehicle-treated mice, tumor expansion in the mice that received tamoxifen to activate CreER T2 to delete Dicer slowed dramatically ( Fig. 6D; Ã , P ¼ 0.0288; ÃÃ , P ¼ 0.0005). Analysis of tumors that were equivalent in size before tamoxifen addition, showed significant and increasing apoptosis over time following tamoxifen, as indicated by increased sub-G 1 DNA content ( Fig. 6E; Ã , P ¼ 0.008), Annexin Vpositivity ( Fig. 6F ; ÃÃ , P < 0.0001), and cleaved caspase-3 protein (Fig. 6G) . The consequence of this apoptosis was that the survival of the CreER T2 -activated (tamoxifen) mice was significantly extended ( Fig. 6C ; P ¼ 0.0035, log-rank test).
To assess whether the delayed tumor growth in both experiments and the apoptosis detected was a result of CreER T2 -mediated Dicer deletion, PCR analysis of Dicer gene rearrangement was performed. Surviving lymphoma cells in the mice administered tamoxifen all retained at least one Dicer allele ( Fig. 6H and Supplementary Fig. S3 ) and expressed Dicer protein (Fig. 6G) . Therefore, targeting Dicer deletion, in vivo, induced apoptosis, delaying lymphoma progression and extending survival regardless of when Dicer was deleted.
As a third approach to test the effects of Dicer deletion in lymphomas in vivo, we also injected p53-deleted Dicer fl/fl /Emmyc lymphoma cells expressing CreER T2 and GFP into the blood stream of nude mice; tamoxifen or vehicle control administration began on the same day. By day 17 and certainly by day 21, vehicle control-treated mice had more lymphoma cells present in their blood compared with mice that received tamoxifen to activate CreER T2 and delete Dicer ( Fig. 6I ; Ã , P < 0.0001 and Supplementary Fig. S4 ). Furthermore, mice that had activated CreER T2 (tamoxifen) lived significantly longer than control mice ( Fig. 6J; P < 0.0001, log-rank test) . Collectively, all three in vivo experiments show that deleting Dicer in B-cell lymphomas leads to apoptosis and decreased lymphoma cell expansion, providing evidence that targeting Dicer in B-cell lymphomas may have therapeutic potential even when lymphomas lack a functional p53 pathway.
Discussion
Previously, we detected an increase in p53 inactivation in Bcell lymphomas from CD19-cre þ /Dicer fl/fl /Em-myc mice (19) , suggesting a connection between p53 activation and Dicer deletion. Moreover, we also observed that Dicer deletion in untransformed MEFs increased p53 levels and induced a premature senescent phenotype that could be delayed by deleting either the Ink4a/Arf or p53 locus (21) . Others reported a fraction of a murine p53-null, mutant K-Ras-expressing sarcoma cell line and SV40-immortalized, and thus p53-and Rb-inactivated, mesenchymal stem cells could survive Dicer deletion (23) . Although the data pointed to p53 being a critical mediator of the deleterious effects of Dicer deletion, we show here that loss of p53 could not rescue the profound apoptosis that occurs in primary B cells and B-cell lymphomas upon Dicer deletion. All approaches to obtain p53-null B cells or B-cell lymphomas that had biallelic Dicer deletion resulted in one Dicer allele being retained in any surviving cells, whereas Dicernull fibroblasts could be easily generated. These results that indicate Dicer, and consequently miRNA, have essential functions in B-cell survival for both untransformed and malignant B cells that cannot be overcome by loss of p53. Also, lymphomas that lacked Arf could not survive Dicer deletion, indicating that inactivation of the p53 pathway is insufficient to allow B-cell lymphoma survival. Moreover, the data show that all stages of B-cell transformation from immortalized (p53-null) to transformed (lymphoma) require Dicer. In addition, a deficiency in Dicer and Rb combined with p53 inactivation resulted in synthetic lethality in retinal progenitors (24) . Therefore, although p53 inactivation may provide protection from the deadly effects of Dicer deletion in some cellular contexts when specific genetic alterations are present, Dicer loss is lethal for B cells and B-cell lymphomas regardless of p53 status. Our results did show that a deficiency in p53 was able to rescue several aspects of Myc-induced B-cell lymphoma development in the Dicer starting the day of injection (A; P ¼ 0.0012, log-rank test) or once lymphomas were 90 to 150 mm 3 (C; P ¼ 0.0035, log-rank test). Arrow, the day tamoxifen administration began for C. The number (n) of mice is indicated. B and D, tumor volumes for mice in A and C, respectively, were measured at the indicated intervals (for B: Ã , P ¼ 0.0051; ÃÃ , P < 0.003; for D: Ã , P ¼ 0.0288; ÃÃ , P ¼ 0.0005). D, arrow, the day tamoxifen administration began. E-G, apoptosis was measured at intervals following tamoxifen or vehicle control administration in matched tumor pairs by propidium iodide (PI) staining of fragmented (sub-G1) DNA (E), Annexin V/7-AAD staining (F), and cleaved caspase-3 protein detection (G). Representative data (left) and mean values at 48 hours (right) are shown for E and F; Ã , P ¼ 0.0008; ÃÃ , P < 0.0001, t tests. Western blot analyses of whole-cell lysates for the proteins indicated (G). H, PCR product analysis of Dicer gene rearrangement of the mice from C. Controls for G and H include protein lysates or DNA from CreERT2-expressing Dicer fl/fl MEFs treated with 4-OHT or ethanol. I and J, nude mice were injected intravenously with CreER T2 -expressing p53-deleted Dicer fl/fl /Em-myc lymphoma cells (DC1020) and administered tamoxifen or corn oil vehicle control starting the same day.
Blood was assessed for GFP-positivity by flow cytometry at intervals after lymphoma injection. Representative data (left) and mean values for the indicated number of mice are shown (I; Ã , P < 0.0001, t test). Kaplan-Meier survival curves (J; P < 0.0001, log-rank test).
in B-cell lymphoma phenotype and the rare development of Tcell lymphomas are currently unclear, but likely involve protection from apoptosis of a lymphoid progenitor, allowing differentiation to continue along B-and T-cell lineages. In addition, although CD19 surface expression was restored in the pre-B/B-cell lymphomas that emerged, 57% of the lymphomas lacked or had reduced Cre protein expression. This was unexpected, as all lymphomas expressed CD19 and Cre is driven from the CD19 promoter. Although Cre expression was downregulated in half of the lymphomas, the frequency of its expression (43%) was significantly higher than that of 12% in the CD19-cre /Em-myc mice (19) . These results indicate that while more lymphomas expressed Cre, the lymphomas still prevented it from deleting both Dicer alleles. Our data show that a p53 deficiency still resulted in a delay in lymphoma development and did not allow biallelic Dicer deletion, but it did restore the lymphoma phenotype and CD19 surface expression and partially restored Cre expression in the B-cell lymphomas.
Protection from apoptosis is a critical step in B-cell development and lymphomagenesis (28, (32) (33) (34) . Expression of Cre in Dicer fl/fl mice results in early B-cell progenitor (Mb1-Cre) or mature B-cell (Aicda-Cre) apoptosis and a developmental block or a lack of germinal centers, respectively (22, 35) . Suppressing apoptosis by overexpressing the antiapoptotic Bcl-2 protein and/or deleting the proapoptotic gene Bim or by expressing an immunoglobulin transgene, which provides survival signals, partially rescued B cells from apoptosis in these systems. Because neither study confirmed biallelic deletion of Dicer had indeed occurred in the surviving B cells, and because our data show that B cells do not survive Dicer deletion, it is likely that the B cells that survived in their studies only deleted one allele of Dicer. Moreover, the reduction in apoptosis that allowed more B cells to survive and differentiate likely reflects effects on the B-cell compartment rather than on the survival of Dicer-deleted B cells. In addition, it is unlikely that Bcl-2 overexpression alone would protect an untransformed B-cell from apoptosis induced by Dicer deletion, as the B-cell lymphomas we evaluated overexpressed Bcl-2 (unpublished data) and rapidly died when Dicer was deleted. However, these results could also indicate that transformed B cells rely on Dicer more than untransformed B cells. Certainly, further studies are needed to determine the conditions, if any, under which B cells at any maturation stage would survive complete Dicer ablation.
Dicer is reported to function as a haploinsufficient tumor suppressor and promote tumorigenesis in retinal, lung epithelial, and muscle cells (17, 18) . However, there is a conflicting report on muscle cells (36) . In contrast, the rate of Myc-induced B-cell lymphomagenesis was similar in mice that had one or two alleles of Dicer (19), regardless of p53 status, indicating that Dicer was not a haploinsufficient tumor suppressor in B cells. Moreover, the evaluation of Dicer protein and function in p53 þ/À /CD19-cre þ /Dicer fl/fl /Em-myc lymphomas with one or two Dicer alleles revealed analogous levels of protein and mature miRNA. Therefore, loss of one allele of Dicer did not change the levels of Dicer protein or function in the B-cell lymphomas. Although our results reveal Dicer inhibition as a potential therapeutic opportunity for treatment of B-cell lymphomas, which are sensitive to Dicer loss, due to its haploinsufficient tumor suppressor functions in other cell types, this may not be possible. Therefore, it will be important in future studies to determine the cell types in which Dicer functions as a haploinsufficient tumor suppressor, and whether transient inactivation of Dicer could be therapeutic for lymphoma treatment without being tumor-inducing.
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